Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group Academic Article uri icon

Overview

MeSH Major

  • Cyclophosphamide
  • Drug Resistance, Neoplasm
  • Neoplasm Recurrence, Local
  • Neoplasms
  • Oncolytic Virotherapy
  • Picornaviridae
  • Salvage Therapy

abstract

  • NTX-010 is feasible and tolerable at the dose levels tested in pediatric patients with relapsed/refractory solid tumors either alone or in combination with cyclophosphamide. However, despite the addition of cyclophosphamide, neutralizing antibodies appeared to limit applicability.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4376652

Digital Object Identifier (DOI)

  • 10.1002/pbc.25269

PubMed ID

  • 25307519

Additional Document Info

start page

  • 743

end page

  • 50

volume

  • 62

number

  • 5